Key indicators: single-crystal X-ray study; T = 120 K; mean (C-C) = 0.004 Å; R factor = 0.037; wR factor = 0.097; data-to-parameter ratio = 18.5. 
In the title compound, [Zn 2 Cl 4 (C 22 H 18 N 4 ) 2 ]Á2C 3 H 7 NO, the 1,3-bis[(benzimidazol-1-yl)methyl]benzene ligand bridges two ZnCl 2 units, forming a centrosymmetric dinuclear molecule. The Zn II atom shows a distorted tetrahedral coordination within a Cl 2 N 2 donor set.
Related literature
For the crystal structure of 1,3-bis((benzimidazol-1-yl)methyl)benzene, which was isolated as the malonic acid co-crystal, see: Aakerö y et al. 
Data collection
Bruker SMART APEX diffractometer Absorption correction: multi-scan SADABS (Sheldrick, 1996) T min = 0. 
Experimental
The compound was prepared from a mixture of boric acid (0.17 g), zinc chloride (0.27 g), 1,3-bis((benzimidazol-1-yl)methyl)benzene (0.45 g) in DMF (3.6 ml) and water (0.2 ml). The mixture was sealed in 25-ml Teflon-lined stainlesssteel vessel, which was heated at 423 K for 5 days. The vessel was then cooled to room temperature slowly. Crystals were picked out manually.
Refinement
Carbon-bound H-atoms were placed in calculated positions (C-H 0.95 to 0.99 Å) and were included in the refinement in the riding model approximation, with U(H) fixed at 1.2U eq (C). (10 
